Viewing Study NCT00112203



Ignite Creation Date: 2024-05-05 @ 11:44 AM
Last Modification Date: 2024-10-26 @ 9:12 AM
Study NCT ID: NCT00112203
Status: COMPLETED
Last Update Posted: 2017-02-08
First Post: 2005-05-31

Brief Title: Long-Term Safety and Efficacy of Itopride Hydrochloride HCl in Patients Suffering From Functional Dyspepsia
Sponsor: Forest Laboratories
Organization: Forest Laboratories

Study Overview

Official Title: A Multicentre Open-Label Extension Phase to Study the Long-Term Safety and Efficacy of Itopride HCl in Patients Suffering From Functional Dyspepsia
Status: COMPLETED
Status Verified Date: 2017-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Itopride is a compound already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton It is used to treat symptoms of functional dyspepsia Patients suffering from this condition have difficulties digesting food Patients feel full after eating they have bloating and have stomach pain The goal of this study is to see if itopride helps to relieve the symptoms of functional dyspepsia on a long-term basis
Detailed Description: All patients who have completed study ITOFD04-03 will be offered to continue to be treated with itopride for a period of up to one year in duration A target of 300 patients will be followed up for 6 months Of these a target of 100 patients will be kept on treatment for an additional 6 months

Patients will need to come to the clinic for evaluations every 8 weeks during the trial Evaluations done at these visits will include lab tests evaluation of the heartburn condition and a questionnaire needed to be completed by the patient to see if the drug is helpful in relieving their symptoms

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None